In one paragraphArticle in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Austin Hammermeister SugerDepartment of Epidemiology, University of Washington School of Public Health, Seattle, Washington.ORCID 0000-0002-6599-2202 Tabitha A HarrisonDepartment of Epidemiology, University of Washington School of Public Health, Seattle, Washington.ORCID 0000-0002-4173-7530 Constance TurmanDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0002-7790-8311 Peter KraftDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0002-4472-8103 Sara LindströmDepartment of Epidemiology, University of Washington School of Public Health, Seattle, Washington.ORCID 0000-0002-7137-7281 Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MSWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2MUSC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI William Dean Wallace · 1985 to 2026
$181.4MTumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MTranslational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8MSouthern Community Cohort StudyR01CA092447 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLOT, WILLIAM J., ZHENG, WEI · 2001 to 2015
$74.0MTISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MValidity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI RIMM, ERIC B · 1991 to 2009
$41.8MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MUnderstanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4MCCR NIH HHS N01 RC037004Intramural NIH HHS Z01 CP010119Intramural NIH HHS Z01 CP010200National Cancer Institute (NCI) CA194393National Cancer Institute (NCI) T32CA09168NCATS NIH HHS UL1 TR000445NCI NIH HHS HHSN261201000006CNCI NIH HHS HHSN261201500005CNCI NIH HHS N01 CN043302NCI NIH HHS N01 CN045165NCI NIH HHS P01 CA033619NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA196569NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA023108NCI NIH HHS P30 CA054174NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA127003NCI NIH HHS P50 CA140388NCI NIH HHS R01 CA034944NCI NIH HHS R01 CA040360NCI NIH HHS R01 CA042182NCI NIH HHS R01 CA056678NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA059045NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA068578NCI NIH HHS R01 CA076366NCI NIH HHS R01 CA081488NCI NIH HHS R01 CA082664NCI NIH HHS R01 CA084979NCI NIH HHS R01 CA092447NCI NIH HHS R01 CA092579NCI NIH HHS R01 CA097193NCI NIH HHS R01 CA121060NCI NIH HHS R01 CA128813NCI NIH HHS R01 CA132839NCI NIH HHS R01 CA133891NCI NIH HHS R01 CA134444NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA140561NCI NIH HHS R01 CA141298NCI NIH HHS R01 CA144040NCI NIH HHS R01 CA148667NCI NIH HHS R01 CA149429NCI NIH HHS R01 CA155101NCI NIH HHS R01 CA188214NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA194393NCI NIH HHS R01 CA197350NCI NIH HHS R01 CA201407NCI NIH HHS R01 CA273198NCI NIH HHS R03 CA130034NCI NIH HHS R37 CA054281NCI NIH HHS R37 CA070867NCI NIH HHS T32 CA009168NCI NIH HHS U01 CA074783NCI NIH HHS U01 CA074794NCI NIH HHS U01 CA074799NCI NIH HHS U01 CA074800NCI NIH HHS U01 CA074806NCI NIH HHS U01 CA086402NCI NIH HHS U01 CA097735NCI NIH HHS U01 CA122839NCI NIH HHS U01 CA137088NCI NIH HHS U01 CA164930NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA167551NCI NIH HHS U01 CA194393NCI NIH HHS U01 CA196386NCI NIH HHS U01 CA206110NCI NIH HHS U10 CA037429NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148107NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148127NCI NIH HHS U19 CA148537NCI NIH HHS U24 CA074783NCI NIH HHS U24 CA074794NCI NIH HHS U24 CA074799NCI NIH HHS U24 CA074800NCI NIH HHS U24 CA074806NCI NIH HHS U24 CA097735NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096300NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA173640NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA182883NCI NIH HHS UM1 CA182910NCI NIH HHS UM1 CA186107NCRR NIH HHS UL1 RR024975NHGRI NIH HHS U01 HG004438NHGRI NIH HHS U01 HG004446NHGRI NIH HHS U01 HG004726NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008INHLBI NIH HHS R01 HL026490NHLBI NIH HHS R01 HL034595NIEHS NIH HHS P30 ES007784NIEHS NIH HHS T32 ES013678NIGMS NIH HHS P20 GM103534NIMHD NIH HHS G12 MD007600NIMHD NIH HHS U54 MD007587
6 · The paper itselfAbstract
backgroundContribution of dominance effects to cancer heritability is unknown. We leveraged existing genome-wide association data for seven cancers to estimate the contribution of dominance effects to the heritability of individual cancer types.
methodsWe estimated the proportion of phenotypic variation caused by dominance genetic effects using genome-wide association data for seven cancers (breast, colorectal, lung, melanoma, nonmelanoma skin, ovarian, and prostate) in a total of 166,772 cases and 284,824 controls.
resultsWe observed no evidence of a meaningful contribution of dominance effects to cancer heritability. By contrast, additive effects ranged between 0.11 and 0.34.
conclusionsIn line with studies of other human traits, the dominance effects of common genetic variants play a minimal role in cancer etiology. IMPACT: These results support the assumption of an additive inheritance model when conducting cancer association studies with common genetic variants.
Indexed as
Genetic Predisposition to DiseaseGenome-Wide Association StudyNeoplasmsCase-Control StudiesFemaleGenetic VariationHumansMalePolymorphism, Single Nucleotide
Identifiers
PMID39018351
PMCPMC11446654
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390